86 related articles for article (PubMed ID: 33141168)
21. miREC: a database of miRNAs involved in the development of endometrial cancer.
Ulfenborg B; Jurcevic S; Lindlöf A; Klinga-Levan K; Olsson B
BMC Res Notes; 2015 Mar; 8():104. PubMed ID: 25889518
[TBL] [Abstract][Full Text] [Related]
22. Tumor Mutation Burden-Related Histopathologic Features for Predicting Overall Survival in Gliomas Using Graph Deep Learning.
Sun C; Luo T; Liu Z; Ge J; Shao L; Liu X; Li B; Zhang S; Qiu Q; Wei W; Wang S; Bian XW; Tian J
Am J Pathol; 2023 Dec; 193(12):2111-2121. PubMed ID: 37741452
[TBL] [Abstract][Full Text] [Related]
23. Japanese version of The Cancer Genome Atlas, JCGA, established using fresh frozen tumors obtained from 5143 cancer patients.
Nagashima T; Yamaguchi K; Urakami K; Shimoda Y; Ohnami S; Ohshima K; Tanabe T; Naruoka A; Kamada F; Serizawa M; Hatakeyama K; Matsumura K; Ohnami S; Maruyama K; Mochizuki T; Kusuhara M; Shiomi A; Ohde Y; Terashima M; Uesaka K; Onitsuka T; Nishimura S; Hirashima Y; Hayashi N; Kiyohara Y; Tsubosa Y; Katagiri H; Niwakawa M; Takahashi K; Kashiwagi H; Nakagawa M; Ishida Y; Sugino T; Takahashi M; Akiyama Y
Cancer Sci; 2020 Feb; 111(2):687-699. PubMed ID: 31863614
[TBL] [Abstract][Full Text] [Related]
24.
Harbin LM; Lin N; Ueland FR; Kolesar JM
Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762518
[No Abstract] [Full Text] [Related]
25. TMBcalc: a computational pipeline for identifying pan-cancer Tumor Mutational Burden gene signatures.
Privitera GF; Alaimo S; Caruso A; Ferro A; Forte S; Pulvirenti A
Front Genet; 2024; 15():1285305. PubMed ID: 38645485
[TBL] [Abstract][Full Text] [Related]
26. Identification and subsequent validation of transcriptomic signature associated with metabolic status in endometrial cancer.
Sidorkiewicz I; Jóźwik M; Buczyńska A; Erol A; Jóźwik M; Moniuszko M; Jarząbek K; Niemira M; Krętowski A
Sci Rep; 2023 Aug; 13(1):13763. PubMed ID: 37612452
[TBL] [Abstract][Full Text] [Related]
27. Signaling-induced systematic repression of miRNAs uncovers cancer vulnerabilities and targeted therapy sensitivity.
Wurm AA; Brilloff S; Kolovich S; Schäfer S; Rahimian E; Kufrin V; Bill M; Carrero ZI; Drukewitz S; Krüger A; Hüther M; Uhrig S; Oster S; Westphal D; Meier F; Pfütze K; Hübschmann D; Horak P; Kreutzfeldt S; Richter D; Schröck E; Baretton G; Heining C; Möhrmann L; Fröhling S; Ball CR; Glimm H
Cell Rep Med; 2023 Oct; 4(10):101200. PubMed ID: 37734378
[TBL] [Abstract][Full Text] [Related]
28. Symptom-correlated MiRNA signature as a potential biomarker for Kawasaki disease.
Chen CC; Chu HY; Chang IY; Chang YS; Weng KP; Chang LS; Liu SF; Kuo HC
Biomed J; 2023 Dec; ():100684. PubMed ID: 38086470
[No Abstract] [Full Text] [Related]
29. The interplay of sex steroid hormones and microRNAs in endometrial cancer: current understanding and future directions.
Thakur L; Thakur S
Front Endocrinol (Lausanne); 2023; 14():1166948. PubMed ID: 37152960
[TBL] [Abstract][Full Text] [Related]
30. Targeting non-coding RNAs to overcome cancer therapy resistance.
Chen B; Dragomir MP; Yang C; Li Q; Horst D; Calin GA
Signal Transduct Target Ther; 2022 Apr; 7(1):121. PubMed ID: 35418578
[TBL] [Abstract][Full Text] [Related]
31. Prognosis Value of microRNA-3677-3p in Lung Adenocarcinoma and Its Regulatory Effect on Tumor Progression.
Zhao J; Yu H; Han T; Zhu X
Cancer Manag Res; 2021; 13():9261-9270. PubMed ID: 34955656
[TBL] [Abstract][Full Text] [Related]
32. [MiR-671-5p negatively regulates SMAD3 to inhibit migration and invasion of osteosarcoma cells].
Hu Y; Liang D; Chen X; Chen L; Bai J; Li H; Yin C; Zhong W
Nan Fang Yi Ke Da Xue Xue Bao; 2021 Oct; 41(10):1562-1568. PubMed ID: 34755673
[TBL] [Abstract][Full Text] [Related]
33. Identification and validation of a miRNA-related expression signature for tumor mutational burden in colorectal cancer.
Xu L; Zheng Q
World J Surg Oncol; 2021 Feb; 19(1):56. PubMed ID: 33610190
[TBL] [Abstract][Full Text] [Related]
34. Development and Clinical Validation of Novel 8-Gene Prognostic Signature Associated With the Proportion of Regulatory T Cells by Weighted Gene Co-Expression Network Analysis in Uterine Corpus Endometrial Carcinoma.
Liu J; Geng R; Yang S; Shao F; Zhong Z; Yang M; Ni S; Cai L; Bai J
Front Immunol; 2021; 12():788431. PubMed ID: 34970268
[TBL] [Abstract][Full Text] [Related]
35. Integrated analysis of tumor mutation burden and immune infiltrates in endometrial cancer.
Zhou H; Chen L; Lei Y; Li T; Li H; Cheng X
Curr Probl Cancer; 2021 Apr; 45(2):100660. PubMed ID: 33012523
[TBL] [Abstract][Full Text] [Related]
36. MiRNA based tumor mutation burden diagnostic and prognostic prediction models for endometrial cancer.
Lu N; Liu J; Ji C; Wang Y; Wu Z; Yuan S; Xing Y; Diao F
Bioengineered; 2021 Dec; 12(1):3603-3620. PubMed ID: 34252354
[TBL] [Abstract][Full Text] [Related]
37. Targeted literature review on use of tumor mutational burden status and programmed cell death ligand 1 expression to predict outcomes of checkpoint inhibitor treatment.
Krieger T; Pearson I; Bell J; Doherty J; Robbins P
Diagn Pathol; 2020 Jan; 15(1):6. PubMed ID: 32000815
[TBL] [Abstract][Full Text] [Related]
38. miRNA-200a/c as potential biomarker in epithelial ovarian cancer (EOC): evidence based on miRNA meta-signature and clinical investigations.
Teng Y; Su X; Zhang X; Zhang Y; Li C; Niu W; Liu C; Qu K
Oncotarget; 2016 Dec; 7(49):81621-81633. PubMed ID: 27835595
[TBL] [Abstract][Full Text] [Related]
39. An miRNA signature associated with tumor mutation burden in endometrial cancer.
Zhou H; Chen L; Qin M; Lei Y; Li T; Li H; Cheng X
Biosci Rep; 2020 Nov; 40(11):. PubMed ID: 33141168
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
